Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR) issued its quarterly earnings data on Wednesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.02, reports. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $3.72 million.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) traded down 0.05% during mid-day trading on Wednesday, hitting $18.60. 7,102,899 shares of the company’s stock traded hands. Tekmira Pharmaceuticals has a 52-week low of $5.08 and a 52-week high of $31.48. The stock’s 50-day moving average is $12.48 and its 200-day moving average is $15.87. Tekmira Pharmaceuticals also was the recipient of some unusual options trading activity on Monday. Stock traders purchased 10,335 put options on the company. This represents an increase of 999% compared to the average daily volume of 940 put options.

TKMR has been the subject of a number of recent research reports. Analysts at Maxim Group reiterated a “hold” rating on shares of Tekmira Pharmaceuticals in a research note on Friday, August 8th. They now have a $23.00 price target on the stock. On a related note, analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $26.63.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Receive News & Ratings for Tekmira Pharmaceuticals Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekmira Pharmaceuticals Co and related companies with Analyst Ratings Network's FREE daily email newsletter.